Alnylam Pharmaceuticals | ALNY - Cash And Equivalent

Stock Price
328.14
Daily Change
-3.10 -0.94%
Monthly
-22.33%
Yearly
18.81%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $1.49B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Incyte USD 2.93B 508.08M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Moderna USD 1.13B 147M Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Takeda JPY 654.94B 26.55B Dec/2025
Tectonic Therapeutic USD 268.44M 18.94M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025
Xencor USD 28.29M 16.15M Sep/2025